Advanced Solid Phase Synthesis of Goserelin for Commercial Scale-up and Purity

The pharmaceutical industry continuously seeks robust manufacturing routes for critical peptide therapeutics like Goserelin, a potent analog of luteinizing hormone-releasing hormone used in treating prostate and breast cancers. Patent CN104910257B discloses a revolutionary solid phase synthesis process that strategically combines the advantages of both solid and liquid phase methodologies to overcome historical limitations. This innovative approach ensures that the purity of the target peptide is significantly improved while maintaining a relatively high yield throughout the complex multi-step sequence. By implementing a hybrid strategy, the process facilitates feasible intermediate tracing control, which is essential for maintaining stringent quality standards in regulated environments. Furthermore, the entire workflow is designed to be beneficial for amplification and production, addressing the growing global demand for reliable pharmaceutical intermediates supplier partnerships. This technical breakthrough represents a significant leap forward in the cost reduction in API intermediate manufacturing, offering a scalable solution for modern biopharmaceutical needs.

The Limitations of Conventional Methods vs. The Novel Approach

The Limitations of Conventional Methods

Traditional pure liquid-phase fragment synthetic methods, such as those described in prior art like CN101759777A, often suffer from excessively long reaction times during fragment coupling steps, sometimes extending to ten times the duration of conventional reactions. These prolonged processes lead to significant waste of time and resources, while the numerous and diverse reaction steps make the process difficult to control effectively during washing and purification operations. Consequently, the final product purity is often not high, preparing increasing difficulty to purifying and resulting in lower overall yields that are detrimental to large-scale production economics. Additionally, pure liquid-phase fragment condensation methods frequently require double or even triple the amount of raw materials to compensate for losses, causing very big expense to production when amplification is attempted. Although pure liquid-phase synthetic methods can synthesize the purpose product smoothly, these inherent defects regarding time, cost, and control make them less ideal for modern commercial scale-up of complex peptide intermediates requirements.

The Novel Approach

The novel approach presented in the patent data utilizes a solid-liquid combination method that first synthesizes on solid phase before performing liquid phase coupling of semicarbazide, effectively solving the drawback of unmonitored coupling in prior art. This method allows for the tracing detection of semicarbazide coupling effect at any time, ensuring that the reaction progress is fully understood and controlled before proceeding to subsequent steps. By avoiding many side reaction phenomena through careful selection of protecting groups and coupling reagents, the purity of the purpose peptide is improved significantly compared to older techniques. The yield is also of a relatively high level, and the operation facilitates feasible intermediate tracing control, which is crucial for maintaining consistency in high-purity Goserelin production. Whole process is beneficial to amplification and produced, making it a superior choice for reducing lead time for high-purity pharmaceutical intermediates in a competitive market landscape.

Mechanistic Insights into HBTU-DIPEA Catalyzed Solid Phase Coupling

The core of this synthesis lies in the precise utilization of coupling reagent groups such as HBTU/DIPEA in dichloromethane solvent, which greatly shortens the reaction time control for Fmoc-Trp-OH and Fmoc-Ser-OH coupling compared to conventional HOBT/DIC methods. This specific chemical environment minimizes the problem of side reaction and impurity production in two unprotected reactions of amino acid side chains, ensuring a cleaner reaction profile throughout the synthesis. The use of Fmoc-His(Trt)-OH with Trt protection is particularly strategic, as the difference in susceptibility to acid between Trt and tBu allows for selective removal of the Trt reservation while keeping tBu unaffected. This selective deprotection is achieved using a 20% TFA/DCM mixed solution, which eliminates great amount of cost and manpower compared to existing patents that require repeated cracking five times with lower concentrations. The present invention is simple and easy first with raw material Fmoc-His(Trt)-OH participates in reaction because side chain protect side chain is not involved in the reaction in synthesis, will not bring it is corresponding secondary reaction.

Furthermore, the removal of side chain protective groups for arginine and tyrosine, specifically NO2 and Bzl, is successfully achieved using a single hydrogenation step with ammonium formate and Pd/C catalyst. This efficient deprotection strategy involves adding formic acid ammonium and Pd/C by calculating 10% and 5% of quality by thick peptide, carrying out hydrogenation at 40 degrees Celsius for 5 hours to ensure complete removal. The resulting thick peptide methanol solution is then filtered to remove excessive Pd/C and ammonium formate, followed by sample precipitation centrifugation to obtain the thick peptide solid of Goserelin of purity 90%. This method solves the solution for preparing purified in the prior art is that loading goes out higher one of the cost for causing yield to reduce to dichloromethane repeatedly repeatedly. It also solves well in the solution prepared in the prior art to purifying containing substantial amounts of acid, preparing Cheng Zhongxu is neutralized with substantial amounts of alkali with it, can just prepare purifying, and substantial amounts of heat release is understood during whole acid-base neutralization.

How to Synthesize Goserelin Efficiently

The synthesis of Goserelin via this patented route involves a series of carefully orchestrated steps that begin with the loading of Fmoc-Pro-OH onto 2-CTC Resin and proceed through sequential amino acid couplings. Each step is designed to maximize yield and purity while minimizing side reactions, utilizing specific reagents like HBTU/DIPEA and HOBT/DIC under controlled conditions. The detailed standardized synthesis steps see the guide below, which outlines the precise conditions for coupling, deprotection, and final cleavage to ensure reproducibility. This protocol is essential for any laboratory or manufacturing facility aiming to achieve the high standards required for clinical grade peptide production. Following these guidelines ensures that the commercial scale-up of complex peptide intermediates can be achieved with confidence and consistency.

1. Initiate synthesis by coupling Fmoc-Pro-OH to 2-CTC Resin using DIPEA activator followed by Fmoc removal to establish the solid support foundation.
2. Perform sequential amino acid couplings using HBTU/DIPEA or HOBT/DIC systems while maintaining side-chain protection groups like Trt and Bzl for stability.
3. Execute final cleavage and hydrogenation steps using TFA/DCM and Pd/C to remove remaining protecting groups and isolate the crude peptide with high purity.

Commercial Advantages for Procurement and Supply Chain Teams

This innovative synthesis process addresses several critical pain points traditionally faced by procurement and supply chain teams in the pharmaceutical intermediates sector, offering substantial strategic benefits. By eliminating the need for expensive transition metal catalysts in certain steps and simplifying the purification workflow, the method leads to significant cost savings in overall manufacturing operations. The ability to trace intermediates throughout the process enhances supply chain reliability, reducing the risk of batch failures and ensuring consistent delivery schedules for downstream users. Moreover, the simplified waste treatment profile due to reduced solvent usage and avoided heavy metal contamination aligns with increasingly stringent environmental compliance regulations globally. These factors collectively contribute to a more resilient and efficient supply chain, making this method highly attractive for long-term partnerships focused on stability and quality.

• Cost Reduction in Manufacturing: The elimination of complex purification steps and the reduction in raw material overuse directly translate to lower production costs without compromising on the quality of the final active ingredient. By avoiding the need for repeated cracking and neutralization steps that consume large amounts of acids and alkalis, the process reduces the consumption of hazardous chemicals and associated disposal costs. This streamlined approach means that resources are utilized more efficiently, allowing for better margin management in a competitive pricing environment. Consequently, partners can expect a more economically viable production model that supports sustainable growth and investment in further process optimization.
• Enhanced Supply Chain Reliability: The robust nature of this solid-phase synthesis method ensures that production timelines are more predictable and less susceptible to delays caused by purification bottlenecks or batch rejections. With intermediate tracing control, potential issues can be identified and resolved early in the process, preventing costly downstream failures that could disrupt supply continuity. This reliability is crucial for maintaining the steady flow of materials needed for final drug product manufacturing, especially in markets where demand is high and consistent. Partners benefit from a dependable source of high-quality intermediates that supports their own production schedules and market commitments effectively.
• Scalability and Environmental Compliance: The process is designed with amplification in mind, allowing for seamless transition from laboratory scale to commercial production volumes without significant re-engineering of the workflow. The reduced use of hazardous solvents and the avoidance of heavy metal catalysts simplify waste treatment procedures, ensuring compliance with environmental regulations and reducing the ecological footprint of manufacturing. This scalability ensures that supply can meet growing market demand without compromising on safety or sustainability standards. Furthermore, the simplified operational requirements make it easier to implement in various manufacturing settings, enhancing overall flexibility and responsiveness to market changes.

Frequently Asked Questions (FAQ)

The following questions and answers are derived directly from the technical details and beneficial effects outlined in the patent documentation to address common inquiries from industry stakeholders. These insights provide clarity on the specific advantages of this synthesis method regarding purity, efficiency, and scalability for potential adopters. Understanding these technical nuances is essential for making informed decisions about integrating this process into existing manufacturing frameworks. The answers reflect the core innovations that distinguish this approach from conventional methods, highlighting its value proposition for modern pharmaceutical production.

Q: How does this solid-phase method improve purity compared to liquid-phase synthesis?

A: The hybrid solid-liquid approach allows for intermediate tracing and control, significantly reducing side reactions common in pure liquid-phase fragment condensation methods.

Q: What specific protecting group strategy is used for Histidine in this process?

A: The process utilizes Fmoc-His(Trt)-OH where the Trt group is selectively removed with mild acid, avoiding complex operations associated with other protection groups like Fmoc or Mmt.

Q: Is this synthesis method suitable for large-scale commercial production?

A: Yes, the method avoids expensive heavy metal catalysts and simplifies purification, making it highly beneficial for amplification and continuous commercial scale-up.

Partnering with NINGBO INNO PHARMCHEM: Your Reliable Goserelin Supplier

NINGBO INNO PHARMCHEM stands ready to leverage this advanced synthesis technology to deliver high-quality Goserelin intermediates that meet the rigorous demands of the global pharmaceutical market. As a CDMO expert, we possess extensive experience scaling diverse pathways from 100 kgs to 100 MT/annual commercial production, ensuring that your supply needs are met with precision and reliability. Our commitment to stringent purity specifications and rigorous QC labs guarantees that every batch conforms to the highest industry standards, providing you with confidence in your supply chain. We understand the critical nature of peptide therapeutics and are dedicated to supporting your development and commercialization goals through superior manufacturing capabilities.

We invite you to contact our technical procurement team to discuss how this innovative process can benefit your specific project requirements and operational goals. Request a Customized Cost-Saving Analysis to understand the potential economic advantages of adopting this synthesis route for your production needs. Our team is prepared to provide specific COA data and route feasibility assessments to help you make informed decisions about your supply strategy. Partner with us to access cutting-edge technology and reliable supply solutions that drive success in the competitive pharmaceutical landscape.